1. Home
  2. DSY vs IFRX Comparison

DSY vs IFRX Comparison

Compare DSY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSY

Big Tree Cloud Holdings Limited Ordinary Shares

HOLD

Current Price

$0.34

Market Cap

39.9M

Sector

N/A

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.07

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSY
IFRX
Founded
2020
2007
Country
China
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
86.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
DSY
IFRX
Price
$0.34
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
133.7K
904.9K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
120.37
N/A
EPS
0.01
N/A
Revenue
$7,323,356.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,075.42
P/E Ratio
$28.81
N/A
Revenue Growth
16.37
N/A
52 Week Low
$0.32
$0.71
52 Week High
$7.33
$2.77

Technical Indicators

Market Signals
Indicator
DSY
IFRX
Relative Strength Index (RSI) 17.67 42.44
Support Level $0.32 $1.00
Resistance Level $0.43 $1.12
Average True Range (ATR) 0.03 0.09
MACD 0.00 -0.01
Stochastic Oscillator 11.25 36.09

Price Performance

Historical Comparison
DSY
IFRX

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: